Acute and lifetime costs of stroke
| Dates: | 2003 - completed 2004 |
|---|---|
| Funding: | AstraZeneca |
| Collaborators: | Oxford Vascular Study (OXVASC), Department of Geratology, Radcliffe Infirmary, Oxford |
| Information: | Ramon Luengo-Fernandez |
The objective of this study was to estimate the acute and lifetime costs of stroke, based on an analysis of data collected prospectively by Dr Peter Rothwell, as part of the Oxford Vascular Study (OXVASC), on approximately 140 patients with ischemic or haemorrhagic stroke.
In particular, the study's aim was to throw more light on:
- the health care costs associated with the acute treatment phase (approximately the first 3 months after the index event);
- differences in costs between patients referred for community based-follow-up and others;
- the predicted long-term/lifetime costs associated with post stroke morbidity.
Results of this study showed that acute care costs of stroke ranged from £326 (lower decile) to £19,901 (upper decile). There were important interrelations of patient characteristics, stroke subtype, and stroke etiology with hospital admission, length of stay, costs and 30-day case fatality. However, the majority of univariate predictors of resource use, cost, and outcome were confounded by initial stroke severity.
Publications
Luengo-Fernandez, R, Gray, A, Mehta, Z, and Rothwell, P (2004). Acute costs of stroke in the UK National Health Service in 2002-2004.
Value in Health 7(6):692.